Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Law

RPS supports reclassifying cannabis for medicinal use

Ash Soni, president of the Royal Pharmaceutical Society

Source: RPS

Ash Soni, president of the Royal Pharmaceutical Society, said there was “emerging evidence that cannabis may be of benefit to people living with a number of serious conditions”

The Royal Pharmaceutical Society (RPS) has written to home secretary Sajid Javid to express the Society’s support for the rescheduling of cannabis for medicinal purposes.

It submitted an RPS policy statement, which recommends that clinicians should be able to treat patients with cannabis-based medicines “as they feel appropriate”.

The statement says: “The RPS would support moving cannabis to Schedule 2, which would give pharmaceutical scientists greater freedom to research its potential medicinal uses and to carry out clinical trials.”

The policy statement refers to research that has shown that cannabinoids can be used to treat severe refractory epilepsy that has failed to respond to standard anticonvulsant medications, is able to combat appetite loss in patients with cancer and AIDS, and is useful when used as anxiolytics in palliative care.

Ash Soni, president of the RPS, said there was “emerging evidence that cannabis may be of benefit to people living with a number of serious conditions”.

Many countries have already changed the law to facilitate research into this, he added.

On 19 June 2018, Javid announced that a two-part review, led by Sally Davies and the Advisory Council on the Misuse of Drugs (ACMD), would weigh up the benefits and risks of rescheduling cannabis. Javid made clear, though, that the government had no plans to legalise cannabis for recreational use.

The government has also announced the creation of a panel, also led by Davies, which would advise ministers on any applications from senior clinicians to prescribe cannabis-based medicines.

Citation: The Pharmaceutical Journal URI: 20205037

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Ash Soni, president of the Royal Pharmaceutical Society

Supplementary information

Jobs you might like

See more jobs

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.